Abstract
Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.
| Original language | English |
|---|---|
| Title of host publication | Side Effects of Drugs Annual |
| Editors | Sidhartha D. Ray |
| Publisher | Elsevier B.V. |
| Pages | 321-338 |
| Number of pages | 18 |
| ISBN (Print) | 9780128171639 |
| DOIs | |
| State | Published - 2019 |
Publication series
| Name | Side Effects of Drugs Annual |
|---|---|
| Volume | 41 |
| ISSN (Print) | 0378-6080 |
Fingerprint
Keywords
- Adverse effects
- Ethambutol
- Isoniazid
- Leprosy
- Pyrazinamide
- Rifamycins
- Side effect
- Tuberculosis
Cite this
}
Drugs in tuberculosis and leprosy. / Ramanathan, Meenakshi R.; Howell, Crystal K.; Sanders, James M.
Side Effects of Drugs Annual. ed. / Sidhartha D. Ray. Elsevier B.V., 2019. p. 321-338 (Side Effects of Drugs Annual; Vol. 41).Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Drugs in tuberculosis and leprosy
AU - Ramanathan, Meenakshi R.
AU - Howell, Crystal K.
AU - Sanders, James M.
PY - 2019
Y1 - 2019
N2 - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.
AB - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.
KW - Adverse effects
KW - Ethambutol
KW - Isoniazid
KW - Leprosy
KW - Pyrazinamide
KW - Rifamycins
KW - Side effect
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85073527868&partnerID=8YFLogxK
U2 - 10.1016/bs.seda.2019.08.010
DO - 10.1016/bs.seda.2019.08.010
M3 - Chapter
AN - SCOPUS:85073527868
SN - 9780128171639
T3 - Side Effects of Drugs Annual
SP - 321
EP - 338
BT - Side Effects of Drugs Annual
A2 - Ray, Sidhartha D.
PB - Elsevier B.V.
ER -